Activist investor Elliott Investment Management has taken a stake in medical device firm Dexcom Inc. and struck a settlement ...

DexCom stock crashed after the company reported disappointing Q2 results and cut its full-year guidance. This performance raised questions about the potential impact of GLP-1 drugs on DexCom's ...

CEO Jake Leach also discussed the company’s plans for its G8 glucose sensor, dual-analyte sensing and Medicare coverage at an investor day.

Dexcom shares fell Thursday after the company released third-quarter results that beat expectations but showed slow revenue growth. The company's revenue increased 2% from $975 million a year earlier, ...

DexCom reported a sales miss in the second quarter. (Courtesy DexCom) Shares of DexCom were spiraling after the medical device company surprised Wall Street with a steep cut to guidance, and grim news ...

Numerous comments on a Facebook group called “Dexcom G7 – Issues and Complaints” has brought to light a problem that users are referring to as “goose necking.” MD+DI learned more about this issue – ...